Straumann Holding

Straumann is the global premium dental-implant leader — and the only Western medtech company that gives clear-aligner pure-play Align Technology a credible fight via its ClearCorrect business. FY2025 revenue of CHF 2.43 bn (+8.7% organic) makes Straumann the largest pure-play dental-implants company on earth, with a 22% global market share in premium implants and roughly 40% in the premium-aligner second-place spot behind Invisalign.

The 2026 narrative is split between three things. First, ClearCorrect (clear-aligners business acquired 2017) finally crossed 1 million cumulative cases shipped in Q4/2025 — the inflection point sell-side has been waiting for since the GP rollout in EU. Second, the premium-implant pricing power held in 2025 despite Korean and Israeli value-segment competitors (Osstem, MIS Implants) gaining share — Straumann actually raised European prices 4.5% across the BLT+BLX premium line. Third, China: Volume-Based Procurement (VBP) in 2024 cut Straumann's Chinese implant ASP by 67%, but volume tripled. Net: China still slight tailwind, not the existential threat 2024 bears modeled.

The strategic question for 2026: does the ClearCorrect inflection translate into operating-leverage-driven margin expansion, or does Align Technology's price-war response compress both companies?

Top holders Q1/2026: Thomas Straumann family ~32% (founding family, voting control), Capital Group 4.6%, Norges Bank 3.4%, BlackRock 2.8%, Pictet 1.9%. The Straumann family stake means free-float is effectively 60-65%, not 100%, which keeps the stock structurally tight.

What matters: Lindsell Train opened a 1.4% position in Q4/2025, which for a long-duration quality-focused fund signals high conviction. Nick Train has publicly commented that Straumann is the kind of structural-growth medtech name that Lindsell Train prefers over US peers because of the lower-rated Swiss equity tax base and family-controlled discipline.

Insider activity: CEO Guillaume Daniellot exercised options Q1/2026 and sold ~40% (in line with 10b5-1, viewed as routine). Thomas Straumann himself has not transacted since 2018 — extraordinary holder-stability signal. CFO Yang Xu bought CHF 200k of shares in March 2026 at CHF 78 (now CHF 83.62, +7%).

Short interest at 0.8%, near 5-year low — institutional comfort with the China-VBP digestion and ClearCorrect trajectory.

Forward P/E 23.0x against Swiss-medtech peer median of 21x and a Straumann 5-year average of 28x. EV/EBITDA at 16x is at the lower end of the historical 14-20x range. Sell-side PT consensus CHF 100 (range CHF 80-118): JP Morgan most bullish at CHF 118 (assumes ClearCorrect EBIT margin at 22% by 2027), Berenberg CHF 80 (Align price-war base case). The implied probability of a successful ClearCorrect margin inflection in current price is roughly 55-65%. Bull case CHF 125 if ClearCorrect hits margin AND China returns to high-teens growth. Bear case CHF 65 (-22%) if Align price war forces ClearCorrect to defend share rather than expand margin.

1. August 2026: H1/2026 results — ClearCorrect margin trajectory is single most important number
2. Q3 2026: China VBP-base rollover begins — organic growth comparison gets easier
3. January 2027: Align Technology FY2026 results — clarifies whether price war escalates or normalises

Straumann is a Lindsell-Train-style quality-medtech name with two binary call options on top: ClearCorrect margin inflection and China normalisation. I find the moat narrative genuinely strong — the dentist-training ecosystem is not replicable in 5-10 years even with cheaper implants. The 23x forward multiple is rich but not unreasonable for a company that has compounded earnings at 12% CAGR over 15 years through two major recessions. I size STMN as a 2.5-3.5% medtech allocation because the Swiss-franc exposure is a defensive feature I value. Add trigger: any clean H1/2026 print showing ClearCorrect EBIT margin above 18% AND Chinese organic growth above 15%. Bear case is not a thesis-breaker, it just compresses the multiple — the underlying franchise stays intact.